PRINCETON, N.J., June 7 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI) a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL) today announced that RPI has entered into a strategic partnership with Zenotech Laboratories Ltd. (Zenotech Labs) of Hyderabad, India. Based on the agreement, Zenotech Labs will develop, submit for regulatory approval, and manufacture a total of 11 oncology products which Ranbaxy will market as generic formulations in the U.S. and Canada under the Ranbaxy label. The combined annualized sales of these products is $3.7 billion ($US, IMS - MAT: March 2006).
